Use of a T cell-specific monoclonal antibody, T10B9, in a novel allogeneic stem cell transplantation protocol for hematologic malignancy high-risk patients

John S. Thompson, Claire Pomeroy, Richard J. Kryscio, Stephen A. Brown, Donna Reece, Rita Kramer, Dianna S. Howard, Gary vanZant, Suzanne Humphries, Gordon Phillips

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

To reduce the toxicity of traditional conditioning regimens for allogeneic stem cell transplantation (allo-SCT), we used single-agent chemotherapy conditioning with either busulfan (total cumulative dose, 16 mg/kg) or melphalan (200 to 240 mg/m2), followed by the anti-T cell-specific monoclonal antibody T10B9 (MEDI-500) daily for 3 days. T cell-replete SCT was performed from HLA-identical sibling donors. Acute graft-versus-host disease (aGVHD) prophylaxis consisted of 7 additional days of T10B9 and delayed onset of cyclosporine (ie, on day +4 or +5). Twenty-six high-risk hematologic malignancy patients were entered onto this study. All 24 patients who survived longer than 8 days engrafted, although 1 patient experienced late graft failure. Deaths occurred in 21 of 26 patients because of infection (n = 7), progression/recurrence of primary disease (n = 6), aGVHD (n = 4), regimen-related toxicity (n = 1), and other causes (n = 3). Five of these patients are enjoying disease-free survival with a median survival of 1193 days after allo-SCT. The conditioning regimen induced modulation of surface expression of CD3 (but not CD4 or CD8) and was associated with decreasing tumor necrosis factor-α (but not interleukin-6) serum levels. In conclusion, single-agent chemotherapy conditioning with T10B9 produced durable engraftment and long-term survival in some patients who would not have qualified for a traditional allo-SCT.

Original languageEnglish (US)
Pages (from-to)858-866
Number of pages9
JournalBiology of Blood and Marrow Transplantation
Volume10
Issue number12
DOIs
StatePublished - Dec 2004
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Hematologic Neoplasms
Monoclonal Antibodies
T-Lymphocytes
Graft vs Host Disease
Drug Therapy
Busulfan
Melphalan
Survival
Cyclosporine
Disease-Free Survival
Siblings
Interleukin-6
Tumor Necrosis Factor-alpha
Tissue Donors
Transplants
Recurrence
Conditioning (Psychology)
Infection
Serum

Keywords

  • Acute graft-versus-host disease
  • Anti-T cell monoclonal antibody MEDI-500 (T10B9)
  • IL-6
  • Regimen-related toxicity
  • Stem cell transplantation
  • TNF-α

ASJC Scopus subject areas

  • Transplantation

Cite this

Use of a T cell-specific monoclonal antibody, T10B9, in a novel allogeneic stem cell transplantation protocol for hematologic malignancy high-risk patients. / Thompson, John S.; Pomeroy, Claire; Kryscio, Richard J.; Brown, Stephen A.; Reece, Donna; Kramer, Rita; Howard, Dianna S.; vanZant, Gary; Humphries, Suzanne; Phillips, Gordon.

In: Biology of Blood and Marrow Transplantation, Vol. 10, No. 12, 12.2004, p. 858-866.

Research output: Contribution to journalArticle

Thompson, JS, Pomeroy, C, Kryscio, RJ, Brown, SA, Reece, D, Kramer, R, Howard, DS, vanZant, G, Humphries, S & Phillips, G 2004, 'Use of a T cell-specific monoclonal antibody, T10B9, in a novel allogeneic stem cell transplantation protocol for hematologic malignancy high-risk patients', Biology of Blood and Marrow Transplantation, vol. 10, no. 12, pp. 858-866. https://doi.org/10.1016/j.bbmt.2004.09.006
Thompson, John S. ; Pomeroy, Claire ; Kryscio, Richard J. ; Brown, Stephen A. ; Reece, Donna ; Kramer, Rita ; Howard, Dianna S. ; vanZant, Gary ; Humphries, Suzanne ; Phillips, Gordon. / Use of a T cell-specific monoclonal antibody, T10B9, in a novel allogeneic stem cell transplantation protocol for hematologic malignancy high-risk patients. In: Biology of Blood and Marrow Transplantation. 2004 ; Vol. 10, No. 12. pp. 858-866.
@article{17926e69768740db9966b47500ff5225,
title = "Use of a T cell-specific monoclonal antibody, T10B9, in a novel allogeneic stem cell transplantation protocol for hematologic malignancy high-risk patients",
abstract = "To reduce the toxicity of traditional conditioning regimens for allogeneic stem cell transplantation (allo-SCT), we used single-agent chemotherapy conditioning with either busulfan (total cumulative dose, 16 mg/kg) or melphalan (200 to 240 mg/m2), followed by the anti-T cell-specific monoclonal antibody T10B9 (MEDI-500) daily for 3 days. T cell-replete SCT was performed from HLA-identical sibling donors. Acute graft-versus-host disease (aGVHD) prophylaxis consisted of 7 additional days of T10B9 and delayed onset of cyclosporine (ie, on day +4 or +5). Twenty-six high-risk hematologic malignancy patients were entered onto this study. All 24 patients who survived longer than 8 days engrafted, although 1 patient experienced late graft failure. Deaths occurred in 21 of 26 patients because of infection (n = 7), progression/recurrence of primary disease (n = 6), aGVHD (n = 4), regimen-related toxicity (n = 1), and other causes (n = 3). Five of these patients are enjoying disease-free survival with a median survival of 1193 days after allo-SCT. The conditioning regimen induced modulation of surface expression of CD3 (but not CD4 or CD8) and was associated with decreasing tumor necrosis factor-α (but not interleukin-6) serum levels. In conclusion, single-agent chemotherapy conditioning with T10B9 produced durable engraftment and long-term survival in some patients who would not have qualified for a traditional allo-SCT.",
keywords = "Acute graft-versus-host disease, Anti-T cell monoclonal antibody MEDI-500 (T10B9), IL-6, Regimen-related toxicity, Stem cell transplantation, TNF-α",
author = "Thompson, {John S.} and Claire Pomeroy and Kryscio, {Richard J.} and Brown, {Stephen A.} and Donna Reece and Rita Kramer and Howard, {Dianna S.} and Gary vanZant and Suzanne Humphries and Gordon Phillips",
year = "2004",
month = "12",
doi = "10.1016/j.bbmt.2004.09.006",
language = "English (US)",
volume = "10",
pages = "858--866",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Use of a T cell-specific monoclonal antibody, T10B9, in a novel allogeneic stem cell transplantation protocol for hematologic malignancy high-risk patients

AU - Thompson, John S.

AU - Pomeroy, Claire

AU - Kryscio, Richard J.

AU - Brown, Stephen A.

AU - Reece, Donna

AU - Kramer, Rita

AU - Howard, Dianna S.

AU - vanZant, Gary

AU - Humphries, Suzanne

AU - Phillips, Gordon

PY - 2004/12

Y1 - 2004/12

N2 - To reduce the toxicity of traditional conditioning regimens for allogeneic stem cell transplantation (allo-SCT), we used single-agent chemotherapy conditioning with either busulfan (total cumulative dose, 16 mg/kg) or melphalan (200 to 240 mg/m2), followed by the anti-T cell-specific monoclonal antibody T10B9 (MEDI-500) daily for 3 days. T cell-replete SCT was performed from HLA-identical sibling donors. Acute graft-versus-host disease (aGVHD) prophylaxis consisted of 7 additional days of T10B9 and delayed onset of cyclosporine (ie, on day +4 or +5). Twenty-six high-risk hematologic malignancy patients were entered onto this study. All 24 patients who survived longer than 8 days engrafted, although 1 patient experienced late graft failure. Deaths occurred in 21 of 26 patients because of infection (n = 7), progression/recurrence of primary disease (n = 6), aGVHD (n = 4), regimen-related toxicity (n = 1), and other causes (n = 3). Five of these patients are enjoying disease-free survival with a median survival of 1193 days after allo-SCT. The conditioning regimen induced modulation of surface expression of CD3 (but not CD4 or CD8) and was associated with decreasing tumor necrosis factor-α (but not interleukin-6) serum levels. In conclusion, single-agent chemotherapy conditioning with T10B9 produced durable engraftment and long-term survival in some patients who would not have qualified for a traditional allo-SCT.

AB - To reduce the toxicity of traditional conditioning regimens for allogeneic stem cell transplantation (allo-SCT), we used single-agent chemotherapy conditioning with either busulfan (total cumulative dose, 16 mg/kg) or melphalan (200 to 240 mg/m2), followed by the anti-T cell-specific monoclonal antibody T10B9 (MEDI-500) daily for 3 days. T cell-replete SCT was performed from HLA-identical sibling donors. Acute graft-versus-host disease (aGVHD) prophylaxis consisted of 7 additional days of T10B9 and delayed onset of cyclosporine (ie, on day +4 or +5). Twenty-six high-risk hematologic malignancy patients were entered onto this study. All 24 patients who survived longer than 8 days engrafted, although 1 patient experienced late graft failure. Deaths occurred in 21 of 26 patients because of infection (n = 7), progression/recurrence of primary disease (n = 6), aGVHD (n = 4), regimen-related toxicity (n = 1), and other causes (n = 3). Five of these patients are enjoying disease-free survival with a median survival of 1193 days after allo-SCT. The conditioning regimen induced modulation of surface expression of CD3 (but not CD4 or CD8) and was associated with decreasing tumor necrosis factor-α (but not interleukin-6) serum levels. In conclusion, single-agent chemotherapy conditioning with T10B9 produced durable engraftment and long-term survival in some patients who would not have qualified for a traditional allo-SCT.

KW - Acute graft-versus-host disease

KW - Anti-T cell monoclonal antibody MEDI-500 (T10B9)

KW - IL-6

KW - Regimen-related toxicity

KW - Stem cell transplantation

KW - TNF-α

UR - http://www.scopus.com/inward/record.url?scp=10344234290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10344234290&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2004.09.006

DO - 10.1016/j.bbmt.2004.09.006

M3 - Article

VL - 10

SP - 858

EP - 866

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 12

ER -